

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd. *

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

PROPOSED ELECTION OF DIRECTOR

The board of directors (the “**Board**”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) hereby announces that, on 1 March 2024, Mr. YANG Qihua (“**Mr. Yang**”) was nominated as the executive director of the eighth session of the Board of the Company.

The biographical details of Mr. Yang are set out below:

Mr. Yang was born in August 1972. He has obtained a master’s degree in Pharmaceutical Engineering from East China University of Science and Technology. He is a senior engineer. He currently serves as the vice president of Shanghai Industrial Investment (Holdings) Co., Ltd., the vice executive president of Shanghai Industrial Holdings Limited, the party secretary of Shanghai Pharmaceutical (Group) Co., Ltd. and Shanghai Pharmaceuticals Holding Co., Ltd.. Mr. Yang has extensive experience in corporate management. He has served as the party secretary and general manager of Shanghai Sunway Biotech Co., Ltd., the vice chairman and general manager of SIIC Investment Company Limited, the chairman of The Tien Chu (Hong Kong) Company Limited, the vice president of SIIC Investment (Shanghai) Co., Ltd., the chairman of Nanyang Brothers Tobacco Co., Ltd. and the chairman of Wing Fat Printing Company, Limited, etc.

Save as disclosed above, Mr. Yang did not hold any directorships in any other listed companies or any other major positions in the three years prior to the date of this announcement. Save as disclosed above, Mr. Yang does not have any relationship with any director, supervisor, senior management or substantial shareholder or controlling shareholder of the Company. As at the date of this announcement, Mr. Yang does not hold any equity interest in the Company (within the meaning of Part XV of the Securities and Futures Ordinance).

In accordance with relevant requirements of the articles of association of the Company, the appointment of Mr. Yang as the executive director of the Company is subject to the approval of the shareholders at the general meeting. A circular containing, among other things, details of the proposed election of director will be despatched to the shareholders as soon as practicable in accordance with relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”).

If Mr. Yang is elected as the executive director of the Company, the Company will enter into a service contract with him, and his term of office will expire on the same date when the term of eighth session of the Board ends. He will not receive any director’s fee during his term of office.

Save as disclosed above, there are no other matters concerning the election of Mr. Yang as the executive director of the Company that need to be brought to the attention of the shareholders and there are no other matters which shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHONG Tao
Joint Company Secretary

Shanghai, the PRC, 1 March 2024

As of the date of this announcement, the executive directors of the Company are Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive directors are Mr. YAO Jiayong and Mr. CHEN Fashu; and the independent non-executive directors are Mr. GU Zhaoyang, Mr. Manson FOK and Mr. WANG Zhong.

** For identification purpose only*